mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

@article{Elkabets2013mTORC1II,
  title={mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.},
  author={Moshe Elkabets and Sadhna R Vora and Dejan Juric and Natasha Morse and Mari Mino-Kenudson and Taru A Muranen and Jessica J. Tao and Ana Bosch Campos and Jordi Rod{\'o}n and Yasir H. Ibrahim and Violeta Serra and Vanessa S. Rodrik-Outmezguine and Saswati Hazra and Sharat Singh and Phillip Kim and Cornelia Quadt and Manway Liu and Alan Huang and Neal Rosen and Jeffrey A. Engelman and Maurizio Scaltriti and Jos{\'e} Baselga},
  journal={Science translational medicine},
  year={2013},
  volume={5 196},
  pages={
          196ra99
        }
}
Activating mutations of the PIK3CA gene occur frequently in breast cancer, and inhibitors that are specific for phosphatidylinositol 3-kinase (PI3K) p110α, such as BYL719, are being investigated in clinical trials. In a search for correlates of sensitivity to p110α inhibition among PIK3CA-mutant breast cancer cell lines, we observed that sensitivity to BYL719 (as assessed by cell proliferation) was associated with full inhibition of signaling through the TORC1 pathway. Conversely, cancer cells… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Sabatini,mTOR signaling ingrowth control anddisease.Cell149

  • D.M.M. Laplante
  • 2012

Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel

  • A. Huang, C. Fritsch, +6 authors R. Schlegel
  • Cancer Res
  • 2012

Similar Papers

Loading similar papers…